Aphria (NASDAQ:APHA) released its quarterly earnings data on Wednesday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.39), Briefing.com reports. The business had revenue of $160.50 million during the quarter, compared to analysts’ expectations of $153.75 million. Aphria had a negative return on equity of 2.23% and a negative net margin of 18.30%. The company’s revenue was up 33.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.03) EPS.
Aphria stock opened at $12.42 on Friday. The stock has a 50-day moving average price of $7.62 and a 200 day moving average price of $6.45. Aphria has a 52 week low of $1.95 and a 52 week high of $14.01. The company has a current ratio of 5.37, a quick ratio of 3.30 and a debt-to-equity ratio of 0.22.
Several research firms have issued reports on APHA. BMO Capital Markets increased their price objective on Aphria from $7.00 to $15.00 and gave the stock a “market perform” rating in a research report on Friday. Canaccord Genuity upgraded Aphria from a “hold” rating to a “speculative buy” rating and raised their price target for the company from $11.00 to $17.50 in a research report on Friday. CIBC raised their price target on Aphria from $12.50 to $18.00 and gave the company an “outperform” rating in a research report on Friday. Zacks Investment Research cut Aphria from a “hold” rating to a “sell” rating in a research report on Monday, December 28th. Finally, Stifel Nicolaus cut Aphria from a “buy” rating to a “hold” rating in a research report on Thursday, December 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. Aphria has a consensus rating of “Buy” and an average price target of $14.23.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Read More: Average Daily Trade Volume Explained
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.